Canada: Determining Patentable Subject Matter In The United States And Canada

Last Updated: April 11 2012
Article by Melanie Szweras and Micheline Gravelle

As reported in our March 21, 2012, Spring Alert, the United States Supreme Court recently held in Prometheus v. Mayo that certain personalized medicine claims were directed to laws of nature and were thus unpatentable despite containing both an administering step and a determining step. The decision has raised concern amongst biotechnology patent seekers and holders especially in the area of diagnostic methods.

The Prometheus claims were based on the identification of particular ranges of metabolites that are associated with drug efficacy and toxicity. Prior to this, it was known that the levels of the metabolites were correlated with efficacy and toxicity. However, the particular ranges recited in the claims were not known to correlate. The Court was asked to consider whether the method claims contained statutory subject matter although many commentators think the issue of inventiveness appeared more relevant. The Court, in rejecting the claims, pointed to the fact that the claimed steps were conventional, well-known and routine. In the decision, the Court iterated a test for patent eligibility that could have broad applicability. For example, the Supreme Court noted that:

While it takes a human action (the administration of a thiopurine drug) to trigger a manifestation of this relation in a particular person, the relation itself exists in principle apart from any human action. The relation is a consequence of the ways in which thiopurine compounds are metabolized by the body – entirely natural processes. And so a patent that simply describes that relation sets forth a natural law.

Such a strict analysis could have serious implications for the biotechnology industry as many biotechnological inventions relate to a natural process in one way or another. The Court was particularly concerned with whether the claims transformed unpatentable natural laws into patent-eligible applications of those laws. The Supreme Court did go on to concede that new drug claims and new uses of existing drugs would be acceptable.

Since the Supreme Court did not provide much guidance on what is sufficient to transform a law of nature into an application of a law of nature, we must await the interpretation of this case by the lower courts. There is hope that the lower courts will particularize this decision to its set of facts: that doctors had already been administering patients with thiopurine for the treatment of the particular disease and that the levels of metabolites had already been detected after such treatment. But what would have happened if the case that went on appeal had better facts? For example, if a particular polymorphism had been identified to correlate to a specific disease, would the determining step be inventive as it would be detecting the presence of the polymorphism in a particular population of patients, a population that was unknown before this correlation was identified, even though routine molecular biology techniques could be used for such detection? In Prometheus, the claim was found to involve steps that involve well-understood, routine, conventional activity previously engaged in by researchers in the field. In the example given here, the conventional activity of detecting the presence of the polymorphism would not have been previously engaged in by researchers in the field of that particular disease.

The biotechnology community won't need to wait long to find out how far the reach of the Prometheus decision may extend because on Monday, March 26, 2012, the United States Supreme Court asked the Federal Circuit to revisit its decision in the Myriad Case. (For a review on the Myriad Case, please see Appeal Court Confirms that Isolated DNA is Patentable in the U.S.)

The patent at issue in Myriad contained claims to genes, diagnostic methods and screening assays. The Federal Circuit previously held that claims to isolated genes were patentable because the isolated DNA is "markedly different" from that which exists in nature, in particular, the isolated DNA is a distinct chemical entity which has been cleaved or synthesized to consist of a fraction of a naturally occurring DNA molecule.

If the Prometheus decision is given a broad interpretation by the Federal Circuit, some are concerned that since routine, conventional activity is typically engaged in when isolating a DNA sequence, the Prometheus decision could have adverse consequences on claims to genes per se. In particular, some fear that the Federal Circuit will find that the gene sequence is just a product of nature and the additional steps of isolating and purifying the DNA molecule do not transform it into a patentable invention.

The Myriad case also contained diagnostic method and screening assay claims. The Federal Circuit previously held the screening assay claims patentable but found against the diagnostic method claims because the claims used terms such as "analyzing" and "comparing" for identifying the presence of the breast cancer mutations. In particular, the Court held that such steps could be conducting solely in the mind and thus were not patentable. After Myriad, it was thought that adding steps such as "determining" or '"administering" would be sufficient to transform the claim, however, Prometheus has made it clear that more may be needed.

There is no doubt that the biotechnology community will be on pins and needles awaiting the Federal Circuit's review of its Myriad decision, hoping that it will view Prometheus narrowly, relating to its particular facts, where the additional steps were clearly known and used in the prior art.

In Canada, patent eligible subject matter has also been a hot topic of late. In November 2011, the Federal Court of Appeal released its decision in, holding that claims should be given a purposive construction when considering patentable subject matter. On the heels of the decision, the Canadian Intellectual Property Office (CIPO) released three draft practice notices on April 2, 2012, for a 30-day consultation period, including a notice related to Office Practice Respecting Claims to Diagnostic Methods and Medical Uses.

Unfortunately, the CIPO notice puts an emphasis on the "inventive concept" of the claims, a concept that arguably has no basis in Canadian law. This new approach would allow Examiners to ignore portions of a claim that the Examiner deems not to contribute to the inventive concept. The draft notice relating to diagnostic methods cautions:

If, following a purposive construction of the claim, it is determined that the inventive concept includes at least one step of physically acquiring data from an analyte then the inventive concept is statutory. The mere fact that a physical step is identified in a diagnostic method as an essential element for the purposes of determining the scope of the monopoly does not necessarily mean that the subject matter defined by the claim is statutory subject matter. Where a known analyte had been previously assessed using the same or obviously equivalent analytical techniques to those in the claim, the inventive concept of the claim may be limited to the significance, understanding or interpretation of the acquired data. An inventive concept limited to the discovery of the significance of the acquired data, or to its understanding or interpretation, is considered to be abstract or a mental method, and thus not statutory.

This CIPO draft notice seems to be reminiscent of the United States Prometheus decision, essentially ignoring the purposive construction of the claims as a whole, and instead determining whether the additional steps provide an inventive contribution.

The CIPO draft notice does not stop at diagnostic method claims. It goes on to assess the patentability of medical uses, categorically dismissing dosage regime claims despite the fact that there is conflicting case law on the status of such claims.

The CIPO practice notice is a draft and we believe that there will be a huge push back from the biotechnology industry as well as from the patent bar, which hopefully will be able to convince CIPO that this notice goes far beyond the current state of law in Canada.

Unfortunately, the Prometheus decision and the recent draft CIPO practice notices appear to be signalling a new era for patenting of biotechnology in both the United States and Canada. As such, patentees should ensure that applications include as many different types of claims as possible, such as methods, kits, compositions, and methods of medical treatment/uses. In addition, patentees should consider various fall-back dependent claims that provide particular steps with an emphasis on anything that is considered non-conventional in order to keep options open until the ramifications of the Prometheus and Amazon decisions are known. Patentees are encouraged to contact us for further advice.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Melanie Szweras
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions